Intensity Therapeutics

🔒CT biotech firm regains Nasdaq compliance after carrying out reverse-stock split

Intensity Therapeutics, Inc., a Shelton-based biotechnology company, has regained compliance with Nasdaq listing requirements, about three weeks after it executed a reverse-stock split. The company said Friday it received notice […]

🔒CT biotech firm plans reverse stock split to regain Nasdaq compliance

Intensity Therapeutics Inc., a Shelton-based biotechnology company, said its board has approved a 1-for-25 reverse stock split of the company’s common stock.

🔒Shelton cancer-drug startup looks to Big Pharma after clinical trial pause

Shelton biotech Intensity Therapeutics paused its Phase 3 cancer trial after running low on cash. The company needs $30M to finish testing INT230-6, an injectable drug that attacks tumors directly.

Shelton biotech to raise $4M for novel cancer therapy

Shelton-based Intensity Therapeutics said it will raise $4 million in a direct stock offering to a new...

- Advertisement -

CT-based biotech moves ahead with reverse-split plan

Intensity Therapeutics Inc., a clinical-stage biotechnology company based in Shelton, announced this week that its shareholders have approved a reverse stock split.

🔒Shelton-based biotech regains Nasdaq compliance

A clinical-stage biotechnology company said it received a letter from the Nasdaq Stock Market confirming it had met the minimum $2.5 million stockholders’ equity requirement.